Could two antibodies replace daily HIV pills? new study aims to find out.
NCT ID NCT06987318
First seen Nov 12, 2025 · Last updated May 24, 2026 · Updated 29 times
Summary
This early-stage study tests whether two lab-made antibodies can safely help people with HIV keep the virus under control after stopping their daily antiretroviral therapy. The study involves 40 adults who started HIV treatment very early after infection. Participants will receive the antibodies and then pause their regular medication under close monitoring to see if the antibodies alone can suppress the virus.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Alabama CRS
Birmingham, Alabama, 35222, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Barranco CRS
Lima, 15063, Peru
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Chapel Hill CRS
Chapel Hill, North Carolina, 27599-7215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Houston Advancing Research Team CRS
Houston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS
Rio de Janeiro, 21040-900, Brazil
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Instituto de Pesquisas em AIDS do Rio Grande do Sul - IPARGS CRS
Porto Alegre, Rio Grande do Sul, 91350-180, Brazil
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Massachusetts General Hospital CRS (MGH CRS)
Boston, Massachusetts, 02114, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Northwestern University CRS
Chicago, Illinois, 60611, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Ohio State University CRS
Columbus, Ohio, 43210, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Penn Therapeutics CRS
Philadelphia, Pennsylvania, 19104, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Ponce de Leon Center CRS
Atlanta, Georgia, 30308-2012, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
UCSD Antiviral Research Center CRS
San Diego, California, 92103, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Colorado Hospital CRS
Aurora, Colorado, 80045, United States
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.